Awards & Advancement

BioDelivery Sciences appoints Thomas W. D'Alonzo to board of directors

Tuesday, April 30, 2013 08:00 AM

BioDelivery Sciences International, a specialty pharmaceutical company, has appointed Thomas W. D'Alonzo to the company's board of directors.

More... »

PAREXEL honored with 2013 "Partnership Pioneers of the Year" Award

Monday, April 29, 2013 11:09 AM

PAREXEL International, a global biopharmaceutical services provider, has been named a recipient of the 2013 "Partnership Pioneers of the Year" award in recognition of its innovative strategic partnership with Pfizer and ICON.

More... »

David A. Dodd appointed president and CEO of Aeterna Zentaris

Friday, April 26, 2013 03:05 PM

Aeterna Zentaris, an oncology and endocrinology drug development company, has appointed David A. Dodd as president and CEO, succeeding Juergen Engel, PhD. Dodd has also been appointed director on the company's board of directors.

More... »

Quintiles wins Best CRO Award at World Vaccine Congress 2013

Friday, April 26, 2013 11:06 AM

For the second consecutive year, Quintiles has been named Best Clinical Research Organization (CRO) in the Vaccine Industry Excellence (ViE) Awards. Presented at the World Vaccine Congress, the awards recognize and celebrate individuals, organizations and initiatives which have made significant contributions over the past 12 months.

More... »

VentiRx Pharmaceuticals appoints James Kyle Bryan as CMO

Thursday, April 25, 2013 08:00 AM

VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company focused on novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases, has appointed James Kyle Bryan, M.D., as chief medical officer. 

More... »

Oramed appoints Hexter as COO, vice president of business development

Monday, April 22, 2013 08:00 AM

Oramed Pharmaeuticals, a developer of oral drug delivery systems, has appointed Joshua Hexter as chief operating officer and vice president of business development.

More... »

Orexigen CEO Michael Narachi elected to PhRMA board of directors

Monday, April 22, 2013 08:00 AM

Michael Narachi, president and CEO of Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a term of two years.

More... »

Lynn Kramer appointed chief clinical officer of Eisai Product Creation Systems

Friday, April 12, 2013 02:13 PM

Eisai has appointed Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems.

More... »

BMS appoints Francis Cuss as executive vice president, CSO

Monday, April 8, 2013 03:00 PM

Bristol-Myers Squibb, a global biopharmaceutical company, has appointed Francis Cuss, MB, BChir, FRCP, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., retires.

More... »

EntreMed announces changes to board of directors, CEO appointment

Friday, April 5, 2013 12:05 PM

The board of directors of EntreMed, a clinical-stage pharmaceutical company focused on cancer, has appointed two new individuals as directors. Joining the board are James Huang and Y. Alexander Wu, Ph.D.

More... »